SG11202012091WA - General amyloid interaction motif (gaim) - Google Patents

General amyloid interaction motif (gaim)

Info

Publication number
SG11202012091WA
SG11202012091WA SG11202012091WA SG11202012091WA SG11202012091WA SG 11202012091W A SG11202012091W A SG 11202012091WA SG 11202012091W A SG11202012091W A SG 11202012091WA SG 11202012091W A SG11202012091W A SG 11202012091WA SG 11202012091W A SG11202012091W A SG 11202012091WA
Authority
SG
Singapore
Prior art keywords
seq
gaim
amyloid
polypeptide
disease
Prior art date
Application number
SG11202012091WA
Other languages
English (en)
Inventor
Rajaraman Krishnan
Eva Asp
Ming Proschitsky
Richard Fisher
Original Assignee
Proclara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proclara Biosciences Inc filed Critical Proclara Biosciences Inc
Publication of SG11202012091WA publication Critical patent/SG11202012091WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202012091WA 2018-06-15 2019-06-14 General amyloid interaction motif (gaim) SG11202012091WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685757P 2018-06-15 2018-06-15
US201862749499P 2018-10-23 2018-10-23
PCT/US2019/037179 WO2019241628A1 (en) 2018-06-15 2019-06-14 General amyloid interaction motif (gaim)

Publications (1)

Publication Number Publication Date
SG11202012091WA true SG11202012091WA (en) 2021-01-28

Family

ID=67263052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012091WA SG11202012091WA (en) 2018-06-15 2019-06-14 General amyloid interaction motif (gaim)

Country Status (13)

Country Link
US (2) US11692017B2 (enExample)
EP (2) EP3806884B1 (enExample)
JP (1) JP7549536B2 (enExample)
CN (1) CN112672755A (enExample)
AU (1) AU2019287623B2 (enExample)
BR (1) BR112020025111A2 (enExample)
ES (1) ES2960493T3 (enExample)
IL (1) IL279333B2 (enExample)
MX (1) MX2020013525A (enExample)
PL (1) PL3806884T3 (enExample)
SG (1) SG11202012091WA (enExample)
WO (1) WO2019241628A1 (enExample)
ZA (1) ZA202100071B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3806884B1 (en) * 2018-06-15 2023-08-02 Amyl Therapeutics General amyloid interaction motif (gaim)
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント
CN120641092A (zh) 2022-12-02 2025-09-12 阿尔泽恩股份有限公司 用于用曲米沙特治疗神经变性病症的方法
CN117343200B (zh) * 2023-12-04 2024-01-30 北京质肽生物医药科技有限公司 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US9493515B2 (en) * 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) * 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
JP2016526044A (ja) * 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ, インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージg3pアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드
EP3806884B1 (en) * 2018-06-15 2023-08-02 Amyl Therapeutics General amyloid interaction motif (gaim)

Also Published As

Publication number Publication date
US12247055B2 (en) 2025-03-11
EP4389154A2 (en) 2024-06-26
IL279333B2 (en) 2023-06-01
IL279333A (en) 2021-01-31
US11692017B2 (en) 2023-07-04
CA3102841A1 (en) 2019-12-19
US20210246179A1 (en) 2021-08-12
EP3806884C0 (en) 2023-08-02
WO2019241628A1 (en) 2019-12-19
ES2960493T3 (es) 2024-03-05
JP2021527407A (ja) 2021-10-14
BR112020025111A2 (pt) 2021-04-06
ZA202100071B (en) 2023-04-26
EP3806884B1 (en) 2023-08-02
AU2019287623B2 (en) 2024-11-07
JP7549536B2 (ja) 2024-09-11
EP3806884A1 (en) 2021-04-21
MX2020013525A (es) 2021-02-26
EP4389154A3 (en) 2024-11-13
AU2019287623A1 (en) 2021-01-07
US20230279064A1 (en) 2023-09-07
CN112672755A (zh) 2021-04-16
PL3806884T3 (pl) 2023-11-20

Similar Documents

Publication Publication Date Title
GB201800761D0 (en) Interaction between blockchains
ZA202100071B (en) General amyloid interaction motif (gaim)
ZA202103963B (en) Hot-extraction paper
PL3805545T3 (pl) Cylindryczny element
SG11202101033YA (en) Benzene derivative
GB2576943B (en) Flushing machine
GB201805799D0 (en) b
GB201906000D0 (en) Structural element
GB201900558D0 (en) Concept A2
GB201814379D0 (en) Concept four
GB201900555D0 (en) Concept one
GB201901706D0 (en) b
GB201811625D0 (en) Concept One
HU4942U (hu) Elektrohidraulikus sorompó mûködtetõ szerkezet
GB201814414D0 (en) Concept 36a
GB201811476D0 (en) Hotel
GB201807085D0 (en) Concept 36a
GB201807079D0 (en) Concept 168
GB201807108D0 (en) Concept 156
GB201807117D0 (en) Concept 32
GB201807125D0 (en) Concept 37
GB201807083D0 (en) Concept 29
GB201807124D0 (en) Concept 36
GB201807082D0 (en) Concept 32
GB201807081D0 (en) Concept 23